The endocrine effects and clinical efficacy of the luteinising hormone-releasing hormone (LH-RH) agonist goserelin (Zoladex, ICI plc) as initial hormone therapy for premenopausal advanced breast cancer patients have been previously reported (Nicholson et al., 1984 (Nicholson et al., , 1985 Williams et al., 1986; Walker et al., 1986) . In a study of 53 premenopausal patients we reported a response rate to goserelin of 31%; comparable to our previous experience of surgical oophorectomy Buchanan et al., 1986 ). Recently we have described our experience of combining goserelin with the anti-oestrogen tamoxifen (Robertson et al., 1989a; . Slightly lower levels of serum oestradiol were recorded in those patients receiving combination therapy, along with significant reductions in FSH as compared with goserelin alone. An international multicentre trial is currently underway to determine any clinical advantage of such a combination.
The current paper updates our experience of treating 75 premenopausal advanced breast cancer patients with monthly depot injections of goserelin 3.6 mg; particular address has been given to both the duration of response and survival probability.
Patients and methods
Seventy-five premenopausal patients with histologically proven advanced breast cancer have been treated by the administration of the gonadotrophin releasing hormone agonist goserelin, subcutaneous implantation of a 3.6 mg depot preparation at 28 day intervals. No patient had received previous endocrine or cytotoxic therapies: all gave written informed consent to the administration of the drug. The median age of the patients on commencing therapy was 44 years (range 31-55), with the sites of disease as shown in (Nicholson et al., 1981) . Patients were assessed for response according to UICC criteria (Hayward et al., 1977) . The British Breast Group recommendation that the minimum duration of remission be six months was also adhered to (British Breast Group, 1974) .
Statistical methods Actuarial survival analysis was performed using the statistical package SPSSX-21 (SPSS, 1986) life table analysis which calculates Gehan's generalised Wilcoxon rank test for censored data (Lee & Desu, 1972) .
Results
Twenty-five of the 75 patients (33%) in whom disease was assessable using the strict clinical criteria of the UICC (Hayward et al., 1977) and the BBG (British Breast Group, 1974) were classified as having shown an objective response to therapy of at least 6 months duration. A complete response (CR) was seen in seven patients (9%), the median duration of which was in excess of 37 months. Three of these responders had stage III disease, while four had locoregional recurrence; three of whom also had metastases (two pulmonary, one bone). Static disease (SD) was seen in a further 11 patients (15%), whilst the remaining 39 patients (52%) progressed (PD) within 6 months of starting goserelin. Duration of response is recorded in 
disease progression in response to therapy is summarised in Figure 1 Primary tumour oestrogen receptor (ER) status was available in 60 patients (80%); 32 patients were ER positive, and 28 ER negative (see Table III ). Nineteen of the 24 patients responding to goserelin were ER positive, while three had unknown receptor status. Of the seven patients that showed a complete response, six had ER positive primary tumours. Twenty-eight patients had tumours that were ER negative; 21 of these had progressive disease. The oestrogen receptor status of the primary tumour correlates significantly with the prediction of response to goserelin (X2 = 20.59, 6 d.f., P < 0.005).
Discussion
Surgical oophorectomy has become the mainstay of treatment for premenopausal patients with advanced breast cancer since it was first introduced by Beatson at the end of the last century (Beatson, 1896) . This surgical approach suffers many disadvantages in that treatment is palliative and the majority of patients will not respond, thus exposing many to unnecessary and irreversible morbidity (Kennedy et al., 1964) . 7, 7 +, 8, 8 +, 9, 9, 9, 11, 14 +, 14, 14, 15 +, 16 +, 16, 18, 18 +, 22 +, 36 (median 14 +) SD 11 (15%) 6,7,8,9,9, 10+, 10, 16+, 18,37,45+, (median 10 +) PD 39 (52%) Administration of the LH-RH agonist goserelin to premenopausal advanced breast cancer patients produces a rapid desensitisation of the pituitary gland to endogenous LH-RH, with resultant falls in the circulating levels of LH and FSH (Nicholson et al., 1984 (Nicholson et al., , 1985 Williams et al., 1986; . Castrate levels of oestradiol and progesterone are produced within 3-4 weeks although a small group of patients will shown recurrent suppressed peaks of oestradiol . This ability to reduce serum oestradiol is not influenced by either the patients age or weight (Nicholson & Walker, 1989) . A theoretical limiting factor to treatment with LH-RH agonists, as with radiation castration is their inability to immediately suppress ovarian activity; surgical oophorectomy produces castrate levels of oestradiol within 2 to 7 days (Vermeulen, 1976; Beksac et al., 1983) . Despite these theoretical shortcomings we reported a response to goserelin of 31% in a phase I study of 53 premenopausal patients , a value that is comparable to our previous experiences using surgical oophorectomy (Buchanan et al., 1986 ). When we examined the results of 23 assessable patients who had received a combination of goserelin and the antioestrogen tamoxifen we reported a 22% response, with a further 22% of patients showing static disease (Robertson et al., 1989a) .
It is apparent from this study of 75 patients that LH-RH agonists are capable of achieving a significant objective response of worthwhile duration in premenopausal advanced breast cancer patients. We report an objective response rate of 33%, with a median duration of response of 15 months (range 7-52). Seven patients (9%) were classified as having had a complete response, the median duration of which was in excess of 37 months. A further 11 patients (15%) had stable disease of at least 6 months duration (median duration 10 months). This group of patients have a similar survival to those that show responsive disease to at 6 months; this concords to our findings in patients treated with megesterol (Robertson et al., 1989b) . The remaining 39 patients (52%) had disease progression within 6 months of starting treatment.
It would appear that the presence of the oestrogen receptor in the primary tumour may be predictive of a response to medical oophorectomy using goserelin. This is in accordance to our previous findings .
Goserelin is easily administered and produces an effective but reversible castration. Objective remissions of worthwhile duration are seen in a third of patients, comparable to surgical oophorectomy but without its potential and irreversible morbidity, psychological traumas and surgical risks. This is particularly important in that 50% of patients will show no response to the ovarian suppression. Monthly administration also ensures a high patient compliance. 
